ロード中...
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up to 1.5 y followin...
保存先:
| 出版年: | Hum Vaccin Immunother |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8078703/ https://ncbi.nlm.nih.gov/pubmed/33175656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1823778 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|